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Abstract
Background and study aims : In Belgium, 10-15% of patients
infected with the human immunodeficiency virus (HIV) are co-
infected with hepatitis C virus (HCV). Because of increased inci-
dence of antiretroviral drug-related hepatotoxicity and more rapid
clinical evolution towards end-stage liver disease, treatment of
chronic hepatitis C becomes a priority. We report the results of
a multi-centred Belgian study evaluating efficacy and safety of
peginterferon alpha-2b plus ribavirin in HIV-HCV co-infected
patients without AIDS and without decompensated liver disease. 
Patients and methods : Forty-one patients, all genotypes, were
screened to participate. Eventually 37 received treatment with
peginterferon alpha-2b (1.5 µg/kg/week) plus daily weight-based
ribavirin for 52 weeks. About one third of the patients were geno-
types 1, 2/3, and genotype 4, most of the latter being of Central
African origin. About 56% of the patients had severe fibrosis
(Metavir score   F3). 
Results : Sustained viral response (SVR) at 24 weeks of follow-up
was observed in 10/37 (27%) of patients. SVR was higher in geno-
type 2/3 compared to genotype 1/4 (46.7% versus 13.6% ; p = 0.06)
and in low (F0-F1) versus high (F2-F4) grade fibrosis (p = 0.06).
Treatment was withdrawn for side effects in 11/37 patients (30%).
One Child A cirrhosis patient at the start of therapy died 7 months
after treatment withdrawal as a result of severe haemolytic
anaemia.
Conclusions : It can be concluded that weight-based peginterfer-
on alpha-2b plus ribavirin can be successful in selected HIV-HCV
co-infected patients. Caution should be applied in patients with
advanced liver disease. (Acta gastro enterol. belg., 2009, 72, 389-393).
1. Introduction
Human immunodeficiency virus (HIV) and hepatitis
C virus (HCV) infection are major health problems,
worldwide. Although both viruses are transmitted with
high efficacy via direct blood-to-blood contact, HCV is
less easily transmitted via the sexual route than HIV. The
prevalence of HCV co-infection in different geographi-
cal regions is closely related to the prevalence of blood-
borne (mainly intravenous drug abuse) HIV infection.
Within Europe, high rates of HCV co-infection are
observed in the Eastern European countries such as
Belarus or Ukraine, where intravenous drug abuse is the
main route of HIV transmission, HCV co-infection rates
being as high as 70%. Conversely, in Central to Western
European countries such as Belgium, where the main
mode of transmission is via sexual intercourse, HCV co-
infection rates are much lower, between 10-15% (1).
Before the advent of highly active antiretroviral therapy
(HAART), treatment of HIV-HCV co-infected patients
was directed primarily towards managing HIV-related
opportunistic infections with little, if any, attempts to
treat the HCV infection. With the dramatic reduction of
most opportunistic infections in the HIV-infected
patients and the resultant rise in longevity, increasing
numbers of these patients are undergoing assessment and
treatment of HCV infection (2). Further, the increased
incidence of antiretroviral drug-related hepatotoxicity
and the more rapid clinical evolution towards end-stage
liver disease has made treatment of chronic hepatitis C a
priority in these patients (3). Treatment regimens using
interferon alpha (or combination therapy with interferon
alpha + ribavirin) have had lower sustained viral
response rates in co-infected patients than in HCV
mono-infected patients (2). The current standard care for
chronic infection with HCV in individuals without other
infections is pegylated interferon + ribavirin (4). Several
recent trials have found varying rates of sustained viral
response to this combination in HIV-HCV co-infected
patients ; the responses ranging from 27 to 55% (5-14)
and generally lagging behind those in HCV mono-infect-
ed patients. Further, safety issues have been raised in
several of these studies (15). We present here the results
of our multi-centred study evaluating the efficacy and
safety of peginterferon alpha-2b + ribavirin in HIV-HCV
co-infected patients in Belgium.
2. Patients and methods
2.1. Patients
To be eligible for the study, patients had to be aged
18 years or older, to be infected with both HIV and HCV,
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biopsy specimens were centrally scored according to the
Metavir system (16). The activity scores were from 0
(none) to 3 for severe necro-inflammatory activity, and
the fibrosis scores were from 0 (none) to 4 (cirrhosis).
HIV infection was treated, when indicated, according
to the international guidelines available at the moment
of study inclusion. Concomitant medication, including
antidepressants, were allowed to relieve side effects, at
 discretion of the investigators.
2.3. Assessment of efficacy
Serum HCV RNA was measured using a qualitative
PCR assay (Cobas Amplicor HCV test, version 2.0,
Roche Diagnostics ; limit of detection 50 IU/mL) at the
time of screening, at weeks 24 and 52, and at week 24 of
follow-up. HCV RNA was quantified by PCR (Cobas
Amplicor HCV Monitor Test, version 2.0, limit of detec-
tion 600 IU/mL) at baseline. 
The primary efficacy end point was a sustained viro-
logic response (SVR), defined as a serum HCV RNA
level below the assay’s detection limit (< 50 IU/mL) at
24 weeks of follow-up. Patients who had not had HCV
RNA measurement conducted at 24 weeks of follow-up
were considered to have had treatment failure. Viral
genotyping was performed by line probe assay (INNO-
LiPA, Innogenetics, Zwijndrecht, Belgium) at baseline
on entry into the study.
2.4. Assessment of safety
Safety of treatment was assessed by physical
 examination, laboratory tests and spontaneous reports of
clinical adverse events by the patients. The consultation
visits were at weeks 2, 4, 8, 12 and at 6-week intervals
thereafter during the treatment period of up to 52 weeks.
Follow-up visits were for a further 6, 12 and 24 weeks
following the cessation of treatment. Adverse events
were graded according to the World Health Organization
(WHO) scale as mild (grade 1), moderate (grade 2),
severe (grade 3) and life-threatening (grade 4). CD4 cell
counts and HIV-RNA loads were determined at screen-
ing, at baseline, and at weeks 12, 24, 36 and 52, as well
as at weeks 12 and 24 of follow-up. 
The study protocol allowed dose reductions (by half
in the case of peginterferon alpha-2b and by 200 mg per
day but reduction to no lower than 600 mg per day in the
case of ribavirin) when required for the clinical manage-
ment of significant adverse events, or in the case of lab-
oratory analysis abnormalities. If the adverse event was
resolved or improved, a return to the initial dosing level
was permitted at the discretion of the investigator.
Treatment was discontinued if the following had
occurred : virologic non-response at week 24 of treat-
ment, grade 4 adverse events, interruption of therapy for
more than 2 weeks due to patient non-compliance with
treatment and/or due to adverse events, CD4 cell count
decrease to < 200  106/L, rise in HIV RNA load by > log
0.5 above baseline at any time during treatment despite
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to have elevated alanine aminotransferase levels docu-
mented on two or more occasions within the previous
6 months, findings on liver biopsy within the previous
12 months that were consistent with chronic hepatitis C
infection, and compensated liver disease. The diagnosis
of HIV infection was made by positive antibody detec-
tion by ELISA (Enzygnost Anti-HIV ½ Plus, Dade
Behring), further confirmed by INNO-LIA HIVI-II
Score, Innogenetics, Gent, Belgium. Quantification of
HIV-RNA was performed using COBAS AMPLICOR
HIV-1 MONITOR test, v1.5 Ultrasensitive, Roche
Diagnostics (with a detection limit of 50 copies/mL).
HCV infection was confirmed by detection of HCV
RNA using polymerase chain reaction (PCR) assay. For
inclusion in the study, no severe HIV-related immunode-
pression could be present (meaning a CD4 cell count
above > 200  106/L and/or no history of opportunistic
infection within 6 months prior to enrolment). Patients
were not eligible if they had neutropenia (< 1.5  109/L),
thrombocytopenia (< 90  109/L), anaemia (< 11.0 g/dL
haemoglobin), serum creatinine elevated beyond the
 laboratory’s upper limit of normal (ULN), HBsAg posi-
tivity, evidence of decompensated liver disease (total
bilirubin level > ULN, except for non-hepatitis related
factors such as Gilberts disease ; prothrombin time pro-
longed > 3 s ; albumin < 3.5 g/dL ; history or presence of
ascites fluid ; bleeding varices ; or hepatic encephalopa-
thy), severe psychiatric disorders especially depression,
active seizure disorder requiring medication, significant
cardiovascular or chronic pulmonary disease, poorly
controlled diabetes mellitus, auto-immune disorders,
haemophilia or haemoglobinopathies, evidence of active
or suspected malignancy or other clinically significant
coexisting medical conditions. Patients were excluded in
case of alcohol intake > 80 g/d, active illicit drug use
(injection or inhalation) or methadone substitution with-
in 2 years prior to enrolment into the present study.
Women of child bearing potential were not recruited if
they were unwilling to use effective contraception. Also
excluded were potential participants who had received
interferon alpha or ribavirin previously. 
2.2. Study design
The study was conducted in 9 Belgian reference cen-
tres in an open, non-controlled, prospective trial. The
protocol was approved by the ethics committees of the
participating centres. All patients gave their written
informed consent to participation. The study followed
the Helsinki Declaration and Good Clinical Practice
guidelines. Eligible patients were treated with subcuta-
neous injections of 1.5 µg/kg bodyweight peginterferon
alpha-2b (PegIntron®, Schering-Plough, Kenilworth, NJ,
USA) once a week, plus daily ribavirin (800 mg for
patients weighing < 65 kg, 1000 mg if weighing 65-
85 kg, 1200 mg if weighing > 85 kg) for 52 weeks, inde-
pendent of viral genotype. The treatment period was fol-
lowed by a 24-week observation period. Pre-treatment
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modification of the antiretroviral regime. Treatment was
discontinued at the request of the patient or if in the opin-
ion of the attending physician the patient was not benefit-
ing from the treatment or the treatment was detrimental
to the patient’s best interest. In case of premature with-
drawal from the study for whatever reason, the patients
were encouraged to return for follow-up appointments at
6, 12 and 24 weeks after treatment discontinuation and at
the predefined week 52 and 24 weeks of follow-up. HIV
therapy could be modified during the study period at
discretion of the HIV physician, in function of possible
side effect or suspected drug interactions.
2.5. Data presentation and statistical evaluation
The analyses were calculated on an intention-to-treat
basis (all patients who received at least one dose of the
study medication were included in the analyses of effi -
cacy and safety). Continuous variables were expressed
as median and range.
In this study, the responses are end-of treatment and
sustained virologic response. All responses were ana-
lyzed as dichotomous variables.
The relationship between response (dichotomous vari-
able) and a qualitative variable was explored by means of
the Fisher’s exact test. Spearman correlation coefficients
between quantitative variables were computed.
The Student t-test and Kruskal-Wallis test were used
for comparing quantitative variables between 2 groups.
All p values < 0.05 were considered statistically sig-
nificant.
3. Results
3.1. Characteristics of the patients
Between September 2001 and December 2003,
41 patients were screened for the study. Four patients did
not commence treatment either because they chose not to
participate (n = 2) or did not attend the scheduled
appointment for treatment (n = 1) or because of a serious
medical event occurring between screening and the first
treatment (n = 1). These patients were excluded from
analysis. The baseline characteristics of the patients are
presented in Table 1. Of note, two thirds of the study par-
ticipants were receiving an antiretroviral treatment at
inclusion and almost all of them had an undetectable
HIV viral load (< 50 copies/mL). Most HIV treatments
consisted of the combination of one non-nucleoside
reverse transcriptase inhibitor (NNRTI) with 2 nucleo-
side reverse transcriptase inhibitor (NRTI).
3.2. Virologic response
End of treatment virologic response at 52 weeks was
obtained in 14/37 patients (38%). 
SVR at 24 weeks follow-up was observed in
10/37 patients (27%), 7 of whom had genotype 2 and/or
3, while 3 had genotype 1 and none had genotype 4. SVR
for the patients with genotype 1 was 3/11 (27%), 7/15
(47%) for genotypes 2 and/or 3, and 0/11 (0%) for geno-
type 4. 
Three patients were virologic relapsers, all of whom
were genotype 4. In 1 patient with genotype 4 HCV RNA
was not determined at week 24 of follow-up and was,
therefore, considered as treatment failure.
Prior to applying Fisher’s exact test, the HCV geno-
type was grouped in 2 categories for genotype (Genotype
1 or 4 ; Genotype 2 or 3), fibrosis score (low fibrosis :
F0-F1 ; high fibrosis : F2-F4), and HCV viral load (low :
< 850,000 IU/mL ; high :   850,000 IU/mL).
No significant difference with respect to end-of-
treatment response was detected between the two HCV
genotype groups (p = 0.49). The proportion of patients
showing an end-of-treatment response was nevertheless
numerically lower in the HCV genotype 1 or 4 group
(31.8%) than in the HCV genotype 2 or 3 group (46.7%).
A borderline significant difference with respect to
SVR was detected between the two HCV genotype
groups (p = 0.06). The proportion of patients with a
 sustained virologic response was lower in the HCV
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Table 1. — Baseline characteristics of
the included patients (n = 37)
Characteristic N
Age; years, median (range) 34 (17-60)
Gender N (%)
Male 24 (65)
Female 13 (35)
Bodyweight; kg, median (range) 70 (51-125)
Body mass index; kg/m2 median (range), 24 (20-45)
Ethnicity, N
Caucasian 29
Black 7
Asian 1
HCV genotype, N (%)
1 11 (29.7)
2 1 (2.7)
3 13 (35.1)
Co-infection 2 and 3 1 (2.7)
4 11 (29.7)
HCV RNA (n = 34), N (%)
High (  850,000 IU/mL) 18 (53)
Low (< 850,000 IU/mL) 16 (47)
Mode of HCV infection N
Intravenous drug abuse 15
Transfusion 7
Other or unknown 15
Liver fibrosis (Metavir score) (n = 34) N (%)
F0 1 (2.9)
F1 5 (14.7)
F2 9 (26.5)
F3 17 (50.0)
F4 2 (5.8)
CD4 cell count;  106/L, median (range) 481 (222-1169)
HIV RNA (n = 34) N (%)
< 50 copies/mL 22 (65)
> 50 copies/mL 12 (35)
Antiretroviral treatment N (%)
No 13 (35)
Yes 24 (65)
3 NRTI 5
2 NRTI + 1 NNRTI 13
2 NRTI + 1 PI 6
NRTI denotes nucleoside reverse transcriptase inhibitor; NNRTI
non-nucleoside reverse transcriptase inhibitor; PI protease inhibitor.
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ences between the studies (ribavirin dosing, patient
demographic characteristics, HCV genotype distribution,
histological severity) and non-observable differences due
to various forms of bias or measurement error (18). In
our patient group, 56% had bridging fibrosis or cirrhosis
(Table 1) compared to 39% in the RIBAVIC study (7)
and 15% in the APRICOT study (6).
Of particular note was the relatively high proportion
of genotype 4 patients in our population (30%) which is
much higher proportion than HCV mono-infected
patients in Belgium (19). The majority were Sub-
Saharan black patients from Central Africa. None of
these patients achieved SVR. Conversely, relatively
favourable SVR rates are reported in HCV genotype 4
mono-infected patients from the Middle East while SVR
was also reported to be significantly lower in black
African patients (20,21). Whether this is due to ethnicity
or other factors such as HCV genotype 4 sub-types is not
clear.
We had decided, when designing the protocol, to use
bodyweight-based doses of peginterferon alpha-2b and
ribavirin, and to treat all patients for one year, independ-
ent of genotype. Studies have indicated that the use of
bodyweight-based ribavirin in the treatment of co-infect-
ed patients is not associated with an increased risk of
adverse effects, and may be associated with improved
viral response (14,22). Because the efficacy of shorter
treatment duration has not been adequately assessed in
HIV-infected patients, the recommended duration of
treatment is now 48 weeks for co-infected patients,
including those with HCV genotype 2 and 3 (23). 
As in the RIBAVIC study, a high dropout rate because
of side effects was found. One patient eventually died
from invasive pulmonary aspergillosis 7 months after
early discontinuation of treatment at 12 weeks due to the
development of severe Coombs positive haemolytic
anaemia. This patient had a compensated cirrhosis at
start of treatment and the case has been reported previ-
ously (17). 
Several limitations of our study should be kept in
mind. First, the study was non-controlled and the number
of patients was limited. Furthermore, early viral response
was not determined since the concept had not, as-yet,
been established when the study was initiated, only the
24 week stopping rule was applied. Also, at the time of
the study, some patients were treated with a combination
of 3 NRTI, an antiretroviral regimen which is not recom-
mended any more because of lower efficacy on HIV con-
trol. In addition, the numerous drug interactions and
detrimental combinations between HIV and HCV thera-
pies were not yet fully assessed. Some patients received
zidovudine- or stavudine-containing regimens, which are
now strongly discouraged concomitantly with anti-HCV
drugs (23) and which might have been partly responsible
of the high rate of side effects and dropouts. 
We can, however, conclude from our results that the
current standard treatment with bodyweight-based
peginterferon alpha-2b and ribavirin for HCV mono-
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genotype 1 or 4 group (13.6%) than in the HCV geno-
type 2 or 3 group (46.7%). 
There was a trend that patients with low fibrosis (F0-
F1) have higher SVR rate versus patients with high fibro-
sis (  F2) (n/n 6/33, 18% versus n/n 27/33, 82% ; p =
0.06). There was no significant difference in SVR
between high or low HCV-RNA load (p = 0.62).
For the HIV viral load, an indicator was derived using
a cut-off value of 50 copies/mL. No significant differ-
ence with respect to SVR was detected between the two
groups with respect to HIV viral load indicator at screen-
ing (p = 0.6870).
Nine patients were transferred out of the study as per
protocol because of virologic non-response at week 24. 
Nine of 10 patients with SVR received at least 80%
of the prescribed dose of peginterferon plus ribavirin
for at least 80% of treatment period. Only 1 patient who
prematurely withdrew from treatment eventually had a
SVR.
3.3. Safety
Treatment withdrawal due to side effects related to the
study drugs was noted in 11 patients. One of these
patients eventually died from broncho-pulmonary
aspergillosis 7 months after treatment withdrawal. His
case was reported elsewhere (17). Three patients had
treatment interruption due to severe depression, 2 for
severe haemolytic anaemia necessitating transfusion, 2
for drop in CD4 count to < 200  106/L, 1 for pancreati-
tis and hyperglycaemia. Four other patients were treated
with antidepressants, two of them had a SVR. Four addi-
tional patients stopped prematurely due to adverse events
not related to the treatment. 
Specific clinical side effects were flu-like symptoms
(in 73%), symptoms suggestive of psychiatric distur-
bance (62%), anorexia (35%), cutaneous side-effects
(29%), myalgia (27%), headache (22%), hair loss (11%),
vertigo (11%). Anaemia was noted in 19%.
4. Discussion
The regimen used in this open, non-controlled,
prospective, Belgian trial achieved a SVR rate of 27% in
HIV/HCV co-infected patients. SVR was 47% for the
genotype 2/3 patients, 27% in genotype 1, and 0% in
genotype 4 patients. These values are similar to those
from the recently published RIBAVIC study (7) where an
overall SVR of 27% was noted and with significantly
better results in genotype 2/3. We, as well, noted a better
SVR in genotype 2/3 patients compared to genotype 1
and 4 ; albeit the difference was not statistically signifi-
cant and was probably due to low numbers of patients.
There was a trend for better SVR in patients with a low
(F0-F1) compared to high fibrosis score (  F2).
The variability in the reported response rates to pegin-
terferon and ribavirin in HIV/HCV co-infected patients
may be explained, at least in part, by observable differ-
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infected patients can be applied in selected HIV-HCV
co-infected patients despite the SVR rates being lower
than in HCV mono-infected patients. The high dropout
rate due to side effects should be taken into account,
especially when treating patients with advanced liver dis-
ease. The relatively poor outcome, however, calls for
new therapeutic approaches in this setting.
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